Achillion Pharmaceuticals
Blue Bell
About Achillion Pharmaceuticals
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $468.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2017)
- Ticker: nasdaq:ACHN
- Website: achillion.com
- Phone: +215-709-3040
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/achillion-pharmaceuticals-193789 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.